| Name | Title | Contact Details |
|---|---|---|
Sky Dunmyer |
Procurement and Supply Chain Planning | Profile |
Taranis is a leading precision agriculture intelligence platform that uses sophisticated computer vision, data science and deep learning algorithms to effectively monitor fields. Taranis offers a full-stack solution for high precision aerial surveillance imagery to prevent crop yield loss due to insects, crop Farmers lose 30-40% of their yield every season due to crop diseases, insects, and weeds. Our mission: Help growers maximize crop yield, improve productivity, and adopt sustainable practices in order to ensure prosperity, starting in our local communities and for the benefit of the world. Taranis crop intelligence solutions use deep agronomic expertise and the most advanced AI and submillimeter image technologies to do just that. We make an impact for over 100 agribusinesses, thousands of farmers, and in millions of acres around the world, and grow rapidly. Founded in 2015, Taranis raised over $100M from leading VC investors and is being led by a founding team with vast experience in both agriculture and technology.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Aspire General Insurance is a California-based insurance provider that specializes in private passenger auto insurance. Founded in 2012, the company operates in Arizona, California, and Michigan, offering services in both English and Spanish. Aspire has an AM Best rating of B++ (Good) with a Stable outlook, indicating its financial stability. The company focuses on liability and physical damage coverage for private passenger vehicles. It provides 24/7 claims reporting and in-house processing, along with online and mobile tools for policy management, payments, and document access. Aspire offers flexible payment options, including low down payments and installment plans. Their customer support features bilingual call centers and automated solutions for policy updates and claims tracking, ensuring a responsive service experience.
Premia Managing Agency Limited ("PMAL") provides risk-transfer and run-off solutions for other Lloyds syndicates and capital providers. It is responsible for managing the run-off of Syndicate 1884 for the Year of Account 2018, following cessation of live market underwriting on 31 December 2018. PMAL is a subsidiary of Premia Holdings Ltd, a Bermuda based legacy reinsurance group with operations in the USA, Bermuda, UK and EU. PMAL is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.